Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tripterygium glycosides tablet in preparation of drugs for treating CAR-T induced cytokine release syndrome

A technology of cytokines and polyglycosides, applied in the field of medicine, can solve problems such as unclear

Active Publication Date: 2020-10-30
JIANGSU PROVINCIAL HOSPITAL OF TCM
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But it is not clear whether Tripterygium wilfordii can eliminate monocytes in the human body and curb CRS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tripterygium glycosides tablet in preparation of drugs for treating CAR-T induced cytokine release syndrome
  • Application of tripterygium glycosides tablet in preparation of drugs for treating CAR-T induced cytokine release syndrome
  • Application of tripterygium glycosides tablet in preparation of drugs for treating CAR-T induced cytokine release syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Tripterygium glycosides tablets selectively cleared peripheral blood mononuclear cells of patients in vivo without affecting CAR-T cells.

[0023] 1) Two patients diagnosed with CRS after CAR-T cell infusion were given oral low-dose tripterygium glycosides tablets, three times a day, 10 mg each time (total daily dose 0.5 mg / kg), within 36 hours After taking 5 tripterygium glycosides tablets (50 mg), the drug was stopped.

[0024] 2) Take anticoagulant peripheral blood at different time points before and after taking the medicine for routine testing. In addition, take 200 μl of anticoagulant peripheral blood, add 5ml flow cytometry tubes, add fluorescently labeled antibodies HLA-DR-PE, CD14-FITC, and incubate on ice for 30 minutes , after lysing red blood cells, flow cytometry detection.

[0025] 3) qPCR determination of CAR-T cell copy number: EDTA anticoagulated whole blood samples were collected at different time points before and after taking the drug, and...

Embodiment 2

[0031] Example 2 Tripterygium glycosides quickly suppressed CRS.

[0032]Patient 1 was diagnosed with multiple myeloma (IgD, lambda type) in 2017, aged 53 years. His baseline karyotype is 46, XY, +add(1)(p11), -3, del(3)(q13), add(9)(q34), del(11)(p12), add(14) (q32), -17, 18, add(20)(q11), add(22)(q11), +2mar, inc[20]. The patient had an initial partial response to treatment with lenalidomide, bortezomib, and dexamethasone, but his disease worsened after 6 months. Then received 3 cycles of VCLD chemotherapy (bortezomib, cyclophosphamide, lenalidomide and dexamethasone). Subsequent regimens included lenalidomide, bomalidomide, melphalan, vinblastine, epirubicin, and arsenous acid. The patient's bone destruction and anemia worsened, and a bone marrow biopsy showed 52% multiple myeloma cells. In November 2019, the patient participated in a clinical trial of anti-CD19 / BCMA-CAR-T cell therapy. The patient's autologous T cells were transfected with lentivirus to express CD19-s...

Embodiment 3

[0036] Example 3 The treatment of Tripterygium wilfordii Polyglycoside Tablets rapidly suppresses CRS.

[0037] Patient 2 in this example is a 55-year-old female who was diagnosed with B-ALL in 2017. The patient was in complete remission after starting treatment but relapsed 15 months after the initial diagnosis of B-ALL. She did not respond to re-chemotherapy and further intensive chemotherapy, including vindesine, epirubicin, and cyclophosphamide. The patient participated in a clinical trial of anti-CD19-CAR-T cell therapy. The patient's autologous T cells were transfected with lentivirus to express CD19-specific chimeric antigen receptors. Two days prior to cell infusion, the patient was pretreated with chemotherapy (fludarabine at a dose of 30 mg / m 2 Body surface area, cyclophosphamide dose is 600mg / m 2 ), and then the patient was infused with 1.31×10 6 CD3+ cells (0.52×10 per kg 6 CD19-CART cells).

[0038] On the 7th day after the reinfusion of CAR-T cells, the pa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a tripterygium glycoside tablet in preparation of a medicine for treating CAR-T induced cytokine release syndrome. The research finds that the tripterygium glycosides tablet taking the tripterygium glycosides as the main component can be used for rapidly restraining IL-6, IL-8, IL-2, IL-10, IL-1 beta, IFN alpha, IFN gamma and the like, the tripterygium glycosides tablet is orally taken at a low dosage, so that activated mononuclear cells of peripheral blood can be selectively removed, the CRS generated after CAR-T treatment is rapidly restrained, in-vivo CAR-T cells are not affected, a rapid, effective, safe and convenient treatment method can be possibly provided for the CRS, meanwhile, a good cost-benefit ratio is achieved, and the clinical treatment cost of a patient can be greatly reduced. In addition, a positive treatment effect is expected to be achieved on the CRS of a critical patient infected by the novel coronavirus (COVID-19).

Description

technical field [0001] The invention belongs to the field of medicine, and specifically relates to the new medical application of tripterygium glycosides tablets, and more specifically, the application of triptolide in the preparation of drugs for treating CAR-T-induced cytokine release syndrome. Background technique [0002] The main component of tripterygium polyglycoside tablets is tripterygium glycosides, which is extracted and refined from the root of Tripterygium wilfordii Hook F, TwHF, LeiGongTeng, Thunder GodVine through chloroform / methanol. A stable glycoside whose physiological activity is synergistically produced by multiple components (diterpene lactones, alkaloids, triterpenes, etc.), which not only retains the immunosuppressive effects of Tripterygium wilfordii crude drug, but also removes many toxic components. As a Chinese patent medicine, Tripterygium wilfordii Polyglycoside Tablets has been shown to be an effective anti-inflammatory and immunomodulatory dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/37A61K9/20A61P43/00A61P29/00A61K125/00
CPCA61K36/37A61K9/20A61P43/00A61P29/00
Inventor 朱学军孔祥图徐祖琼代兴斌陈碧清田芳姜鹏君
Owner JIANGSU PROVINCIAL HOSPITAL OF TCM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com